Abstract:Abstract From the clinical standpoint, systemic sclerosis (SSc) is characterized by skin and internal organ fibrosis, diffuse fibroproliferative vascular modifications, and autoimmunity. Clinical presentation and course are highly heterogenous and life expectancy variably affected mostly dependent on lung and heart involvement. SSc touches more women than men with differences in disease severity and environmental exposure. Pathogenetic events originate from altered homeostasis favored by genetic predisposition, environmental cues and a variety of endogenous and exogenous triggers. Epigenetic modifications modulate SSc pathogenesis which strikingly associate profound immune-inflammatory dysregulation, abnormal endothelial cell behavior, and cell trans-differentiation into myofibroblasts. SSc myofibroblasts show enhanced survival and enhanced extracellular matrix deposition presenting altered structure and altered physicochemical properties. Additional cell types of likely pathogenic importance are pericytes, platelets, and keratinocytes in conjunction with their relationship with vessel wall cells and fibroblasts. In SSc, the profibrotic milieu is favored by cell signaling initiated in the one hand by transforming growth factor-beta and related cytokines and in the other hand by innate and adaptive type 2 immune responses. Radical oxygen species and invariant receptors sensing danger participate to altered cell behavior. Conventional and SSc-specific T cell subsets modulate both fibroblasts as well as endothelial cell dysfunction. Beside autoantibodies directed against ubiquitous antigens important for enhanced clinical classification, antigen-specific agonistic autoantibodies may have a pathogenic role. Recent studies based on single-cell RNAseq and multi-omics approaches are revealing unforeseen heterogeneity in SSc cell differentiation and functional states. Advances in system biology applied to the wealth of data generated by unbiased screening are allowing to subgroup patients based on distinct pathogenic mechanisms. Deciphering heterogeneity in pathogenic mechanisms will pave the way to highly needed personalized therapeutic approaches.

Role of cellular senescence in the pathogenesis of systemic sclerosis

Molecular Basis of Accelerated Aging with Immune Dysfunction-Mediated Inflammation (Inflamm-Aging) in Patients with Systemic Sclerosis

Senescence and tissue fibrosis: opportunities for therapeutic targeting

Mitochondria, Aging, and Cellular Senescence: Implications for Scleroderma

Advances in epigenetics in systemic sclerosis: molecular mechanisms and therapeutic potential

Pathogenic Roles of Autoantibodies and Aberrant Epigenetic Regulation of Immune and Connective Tissue Cells in the Tissue Fibrosis of Patients with Systemic Sclerosis

Current Concepts on the Pathogenesis of Systemic Sclerosis

Immune Cell Dysregulation As a Mediator of Fibrosis in Systemic Sclerosis

[Progress on Correlation Between Cell Senescence and Idiopathic Pulmonary Fibrosis].

Recent Insights into Cellular and Molecular Mechanisms of Defective Angiogenesis in Systemic Sclerosis

Sirtuins and Accelerated Aging in Scleroderma

Pathogenesis of systemic sclerosis-current concept and emerging treatments

Gene expression meta-analysis reveals aging and cellular senescence signatures in scleroderma-associated interstitial lung disease

Role of Epigenetics in the Pathogenesis of Systemic Sclerosis

Role of B-Cell in the Pathogenesis of Systemic Sclerosis

Unfolding the Pathogenesis of Systemic Sclerosis Through Epigenomics

The role and mechanism of CRISPLD2 in skin fibrosis of systemic sclerosis

Cellular Transdifferentiation: A Crucial Mechanism of Fibrosis in Systemic Sclerosis

Senescence in the ageing skin: a new focus on mTORC1 and the lysosome

Cellular senescence in skeletal disease: mechanisms and treatment

Role of Cellular Senescence in Inflammatory Lung Diseases